September 1st 2025
Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies
Patient Selection for Aflibercept 8 mg
January 31st 2025Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.
Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
January 24th 2025Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.
Significance of the Higher Molar Dose of Aflibercept 8 mg
January 17th 2025Panelists discuss how the aflibercept 8 mg higher molecular concentration enables extended durability through increased VEGF binding capacity and longer intraocular drug levels, potentially allowing for less frequent dosing while maintaining efficacy.
Treat-and-Extend Strategy With Aflibercept
January 3rd 2025Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully determined based on disease activity markers.